First Patient Treated in Clinical Trial for Hematopoietic Stem Cells
The adult stem cell company Fate Therapeutics announces treatment of the first patient in a Phase 1b clinical trial for hematopoietic stem cell support.
May 27, 2009
The adult stem cell company Fate Therapeutics announces treatment of the first patient in a Phase 1b clinical trial for hematopoietic stem cell support.
Embryonic stem cell scientists complain that the new NIH guidelines would severely restrict the federal funding of embryonic stem cell research.
The adult stem cell company Fate Therapeutics has announced a licensing agreement with Children’s Hospital of Boston.
The U.S. Patent and Trademark Office has awarded a patent to Pluristem Therapeutics for the invention of a novel method of expanding hemopoietic stem cells.
Scientists demonstrate that G-CSF can make you smarter.
Scientists demonstrate that adult stem cells from bone grafts extend cardiac transplant survival through immune modulation.
Toll Free:
1-800-980-STEM (7836)
Outside or Inside US Call:
1-954-358-3382
Toll Free Fax (US Only):
1-866-755-3951
From Outside US Fax:
1-775-887-1194
Copyright 2024, Stem Cell Insitute Panama. All rights reserved.